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Abstract 
Ongoing concerns with the security of health information, both from the perspective of the individual patient as well as health systems 
has led to increased attention being given to the potential role of blockchain technology in the secure storage of health information 
through encryption, the integration of diverse health record systems and the vesting of property and access rights to health data in the 
patient. While the security offered by blockchain technology has long been recognized in the finance sector with the emergence of a 
range of cryptocurrencies as a medium of exchange and store of value, demonstrating the value of blockchain technology in health 
management and health technology assessment has yet to be achieved. In this commentary, a number of questions are raised as to 
the potential value offered by blockchain technology as a complement to existing electronic medical record systems. Chief among these 
are: (i) the allocation of property rights as a necessary precondition for blockchain uptake; (ii) access and incentives for active as 
opposed to passive blockchain membership; (iii) monetization of blockchain access; (iv) capturing data from within the blockchain and 
the possibility of value added data; (v) the potential for blockchain platforms in formulary evaluations; (vi) the blockchain as a managed 
market for health data; and (vii) the role of intermediation in blockchain management. 
 




A robust and comprehensive evidence base is critical in health 
care decision-making. The absence of a comprehensive 
evidence base has been recognized as a key element in 
explaining why the US health care system, comprising over 
20% of the US economy, not only delivers health care at a 
higher per capita cost than in comparable developed 
economies but delivers outcomes for the population that lag 
behind those achieved in countries that spend far less. 
Shortfalls in the evidence base are seen in a number of areas. 
Two of the most significant are: (i) a lack of access on the part 
of health system decision makers to information that would 
enable them to monitor and validate, including replicate, the 
claims made by manufacturers for pharmaceutical products 
and devices in target patient populations; and (ii) limited 
access to information by patients that would enable them to 
avoid choosing unnecessarily high cost providers in favor of 
providers who offer high value and cost-effective treatment.  
 
The need for an improved evidence base has been addressed 
by a number of commentaries published in INNOVATIONS in 
Pharmacy over the past 2 years 1. The most recent 
commentary pointed to the importance of distinguishing 
‘evidence’ from information’    in    health    system   decision   
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making 2. Rather than health systems relying on modeled 
claims for comparative product performance, the focus should 
be on establishing platforms to support protocol driven claims 
assessments as part of the formulary evaluation process. It was 
proposed that applications of blockchain technology might 
provide such a platform. The purpose of this commentary is to 
explore in greater depth the potential benefits of blockchains 
as health technology assessment platforms. 
 
The Role of Blockchains 
From a healthcare perspective, the role of a blockchain is to 
overcome the inefficiencies generated by a fragmented health 
information system. Substantial barriers exist to the sharing of 
information between health providers, hospitals, pharmacies 
and laboratories. This is exemplified by the lack of 
interoperability between the variety of electronic medical 
record (EMR) systems, and disparate lab, pharmacy and 
radiology data reporting systems. At the same time,   there are 
increasing concerns over the privacy of health care 
information, its susceptibility to hacking and the uncertainties 
that attach to the ownership of healthcare data. As to this last 
point the issue is not just the ability of third parties to hack 
data systems but the apparent willingness of health systems 
and data collection agencies to sell patient data which is often 
poorly de-identified, to third parties without seeking patient 
consent. 
 
Establishing a blockchain system that stores medical records 
and vests the property rights to those records held or assigned 
to the patient, offers a potentially viable next step. A private, 
decentralized healthcare non-ethereum blockchain offers a 
secure encrypted environment for their healthcare data, giving 
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the patient sole control over access/ownership. This opens the 
opportunity for the patient not only to share these data with 
selected providers, but to monetize their healthcare data for 
research and other applications by third parties through 
tokenization. 
 
With property rights vested in the patient, the patient as 
gatekeeper has the opportunity, presumably with the support 
of market intermediaries, to realize the value implicit in their 
healthcare data that, at the moment, is expropriated by 
insurance companies and other third party data vendors. One 
example would be the ownership of DNA profiles and ability to 
monetize these data through selected access rather than, 
often without the knowledge of the patient, having their data 
sold to third parties. Drug manufacturers, for example, are a 
ready market for DNA profiles in drug development. With 
vested property rights, the patient or the patient’s agent is in 
a position to establish a market price for these data, and for 
the owner to be reimbursed through tokenization. 
 
A healthcare blockchain is a private (for HIPAA requirements) 
decentralized distributed transaction ledger where each block 
represents a real-time transaction between the patient and a 
healthcare provider. Each transaction is linked, creating a 
record embodying cryptographic techniques for full 
transparency and decentralization, creating a trust-less 
consensus rather than a centralized authority overseeing the 
data. Each transaction is validated through a process known as 
mining which validates the transaction or block in a network 
through the application of complex algorithms to prove and 
validate the correctness of a transaction, storing the data in a 
‘block’. Once validated, timestamped and added to the 
blockchain, the transaction cannot be revisited for subsequent 
modification (i.e., immutable). All health data in the blockchain 
are indexed, linking the health data to a unique identifier for 
the patient. Health data from wearable devices and mobile 
applications can be sorted and indexed accordingly. 
Aggregated data from all providers can be captured through 
query or search protocols driven by data dictionaries.  
 
All requests for data access have to be approved by the 
patient, via “opt-in” or “opt-out” choices. There are no 
‘backdoors’ to the system and the likelihood of hacking or 
unauthorized data access is essentially impossible. The patient 
is at liberty, therefore, to approve or deny access and to 
determine which data elements or transactions are open. This 
allows for the monetization of access permissions. One 
approach is to utilize utility tokens within the system where 
smart contracts for data provision can be established at the 
token ‘price’ for those data elements. Tokens can be 
exchanged for cryptocurrency which can then be stored or 
exchanged for fiat dollars in the cryptocurrency markets. 
 
Of course, the ability of patients to monetize their data 
through tokenization, presupposes a market for those data 
and intermediaries that negotiate on behalf of target patient 
groups. This raises the issue of whether blockchain healthcare 
platforms are seen as essentially passive storage devices or as 
an active asset that patients can use to generate income.  In 
the former case, it is not clear who would create and manage 
the blockchain and whether patients would be required to ‘opt 
into’ the blockchain. Presumably, the blockchain would   be 
managed by a commercial entity. The presence of a 
commercially managed blockchain may eliminate the need for 
patients to subscribe to participate in the blockchain. Rather, 
the owners could act as intermediaries to monetize the 
blockchain data through identifying and seeking permissions 
from target patient groups for data access. Under this 
scenario, the blockchain owner would encourage patients to 
participate actively in data access, encouraging (as noted 
below) value added data assembly to enhance the returns to 
the owners and participating patients via tokenization. 
 
Value Added and Blockchains 
There are a number of opportunities open to blockchain 
vendors to develop distributed applications (Dapps) based on 
their various platforms. For these to be considered as viable 
rather than purely speculative, they need to be evidence 
based, driven by protocols with the blockchain management 
providing technical and clinical support. 
 
A range of Dapps could be considered, a number of which 
would meet unmet medical needs in the area of health 
technology assessment. Potential applications could include: 
 
• Claims assessment protocols for new products and 
devices (see below) 
• Tracking and response monitoring for target patient 
populations 
• Clinical trials (focus on replication of claims) 
• Generic and disease specific quality of life assessment 
• Satisfaction with care evaluations 
• Patient reported outcomes assessments in specific 
disease states 
• Risk assessments for medication abuse 
• Risk assessment for adherence and persistence with 
therapy 
• Compliance tracking 
• Wellness and behavioral health incentives (see 
below) 
 
Specific applications could be directed to claims made by 
manufacturers for their products. All too frequently, the 
evidence base for clinical claims is limited. For formulary 
committees to accept claims, they may quite reasonably ask 
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manufacturers to utilize a blockchain platform to report back 
on claims made and those for cost-effectiveness. 
 
As an extension, formulary committees could ask 
manufacturers to undertake comparative claims assessments 
as part of disease area and therapeutic class reviews. Again, 
the blockchain platform could provide the necessary structure 
to support both prospective as well as retrospective 
comparative studies (see below).  
 
Blockchains and Electronic Medical Records 
It should be made clear that a blockchain platform is not a 
substitute for an EMR. While it would be possible to program 
systems such as Epic as a blockchain system, the question of 
property rights is probably best resolved by a blockchain that 
sits alongside and interacts with an EMR platform. After all, if 
a patient moves between providers and health systems, or one 
country to another, questions will arise as to the   ongoing 
ability of the patient’s EMR blockchain to talk to the ‘new’ 
medical record system, and ‘seamlessly’ continue to capture 
and store records. This would apply both to commercial EMR 
platforms as well as to software systems such as the CMS 
Medicare MyMedicare.gov personalized website.  
 
Once a blockchain is in place, and sufficient patients have been 
recruited to the blockchain, a number of opportunities as 
noted above open up for value added activities. One 
opportunity is for the patient to ‘sell’ data elements that are 
captured from the EMR. This would require the application of 
search algorithms together with data dictionaries to identify 
required data elements. Unfortunately, searching EMRs is not 
as straightforward as experience with the University of 
Michigan EMERSE search engine has demonstrated 3. A major 
concern must be the quality of the data in terms of 
incompleteness, inconsistency and inaccuracy. There is not the 
ability to apply a big data model which simply crunches 
millions of administrative claims records.  
 
Rather than just providing access to data captured and 
integrated from the patient’s various provider EMRs the 
ability, as noted above, to utilize the blockchain platform as a 
vehicle for targeting distributed applications, avoids the 
pitfalls associated with developing search engines for EMRs. 
Certainly key data elements could be targeted such as ICD-10-
CM, CPT and NDC codes, but these would be seen as adjunct 
elements to identify patients prior to soliciting their interest in 
specific applications. 
 
The choice of structured questionnaires and reports 
completed at each practice visit by the patient and the 
physician would support data interrogation through a data 
dictionary. This presents the opportunity for integrating 
patient reported outcomes instruments (PROs) in structured 
questionnaires and reports. Reports could be prepared at the 
individual patient level summarizing therapy response over 
baseline, together with reports to capture the distribution of 
therapy responses within the targeted patient group.  
 
Formulary Evaluations 
Over the past two years a number of commentaries have been 
published in INNOVATIONS in Pharmacy pointing to the 
difficulties of establishing and replicating RCT outcomes  
claims made by manufacturers for product performance 
across treating environments. Frequently, formulary 
committees have to rely upon clinical and cost-effectiveness 
claims extrapolated from pivotal randomized trials. Not only 
do these trials often lack external validity in terms of targeted 
treatment populations, but the limited duration of the trial 
doesn’t match real-world evidence treatment cycles. 
 
The need for manufacturers to evaluate and replicate claims 
for their products in real world evidence (RWE) environments 
has been addressed in the recently published Minnesota 
proposed guidelines for formulary evaluation (version2)4. 
Formulary committees would require manufacturers, prior to 
final pricing and tier position decisions, to undertake a 
prospective observational study, to a protocol agreed between 
the parties. The protocol should allow feedback to the 
formulary committee in a short-term, meaningful time frame. 
This allows a full review of the product and its claims in 
targeted treatment populations to be realized. A blockchain 
platform is ideally suited to this purpose 
 
Blockchains and Registries 
Over the past 20 years, considerable resources have been 
devoted to the establishment of registries to track patient 
outcomes. Unfortunately, patients seldom benefit from 
registry participation as property rights are typically 
transferred and vested in the registry owner. As noted in a 
previous commentary, while a blockchain is not a disease 
registry or a single use platform for a specific intervention, it is 
important to note the synergies between disease registries as 
platforms and a blockchain as a platform 1. A blockchain not 
only supports a registry through protocols to generate 
structured healthcare data, but the incentives built into the 
blockchain model with assigned property rights have the 
potential to enhance patient retention in the registry.  
 
The blockchain can be seen as a registry umbrella. Rather than 
creating registries as a response to data limitations, the 
blockchain provides the framework for tracking patients within 
targeted patient populations. Any number of registry analogs 
with built in incentives for patient participation can potentially 
be supported. The added advantage, of course is that the 
blockchain as the repository of the entire medical record offers 
opportunities to link specific applications to track response to 
therapy to that record.  
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Wellness and Behavioral Incentives 
A further potential application of the blockchain model is to 
support programs with the ability to promote future chronic 
disease cost offsets through proactive patient behaviors. 
Incentives could be offered through tokenization for targeted 
patient groups. The ability to do this is not restricted to 
blockchain patient portals. EMR systems have this facility, 
although the form of incentives encompassed would not 
necessarily involve tokens but the more usual incentives of 
cash, vouchers or lottery tickets. Unfortunately, it is not clear 
that behavioral incentives influence behavior. The evidence for 
behavioral incentives is mixed and of low quality. The majority 
of evidence is from non-randomized observational studies 
with only a few well-conducted RCTs. There is no evidence, 
high quality or otherwise, for tokenized incentives within a 
blockchain environment. We have little idea of which 
incentives work best and at what level.  
 
At the same time, any design intended to impact wellness or 
other proactive health behaviors has to recognize the 
possibility of perverse incentives. After all, the French in Indo-
China in the 1920s attempted to reduce the rat population 
through bounties; the result being not a reduction in the rat 
population but the emergence of rat farms to increase supply.  
  
Management and Intermediation 
The potential for blockchains to be credible and to create value 
added outcomes will only be achieved if there is a 
management structure in place that supports intermediation. 
One way of looking at this is to think of the blockchain creating 
a managed market for data transfers and data aggregation. 
The blockchain owner could create this management structure 
or it could be subcontracted. The market brings together 
property owners (patients) as sellers with prospective third 
party clients for the data. Physicians may also participate in the 
value added information assembly (e.g., by generating reports 
to capture clinical endpoints). 
 
Apart from ongoing technical support and marketing of the 
blockchain to prospective clients, successful intermediation in 
the managed market may require a substantial investment by 
blockchain owners in creating a technology assessment skill 
set. The skill set would need to embrace: (i) protocol 
developments and applications in target patient groups to 
evaluate claims; (ii) virtual file creation and de-identification to 
create exportable files; (iii) techniques for claims assessment 
using both aggregate data sets and micro-records; (iv) 
developing platforms for claims assessment to support disease 
area and therapeutic class reviews; and (vi) techniques and 
standards for instrument validation and instrument selection 
to track outcomes in disease areas. 
 
A useful example of value added business service model 
utilizing EMRs is the Clinical Practice Research Datalink (CPRD) 
in the UK. Launched in April 2012, and building upon the earlier 
established General Practice Research Database (GPRD) the 
CPRD provides access to de-identified patient records linked to 
a range of data sets. The database includes demographics, 
diagnoses and symptoms, therapy interventions, outcomes of 
therapy, withdrawal correlates, referrals, laboratory tests and 
lifestyle factors (weight, alcohol use and smoking). To support 
clients, the CPRD staff offer services in 
pharmacoepidemiology, health technology assessment, 
protocol development and research study support.  
 
The first task for any intermediation service would be to 
identify target patient groups from the blockchain patient 
base. If a third party wishes to identify patients by a specific 
ICD-10-CM code, then the blockchain must have a portal or 
window that allows patients with that characteristic to be 
identified prior to seeking permission to access the identified 
patient’s EMR. It seems impractical (and inconsistent), given 
the firewalls in place to protect the data, to allow a ‘backdoor’ 
so that the intermediary can scan quickly the patient 
population to identify (i) the target patient group and (ii) solicit 
access permissions (with smart contracts)  from the patient.. 
Irrespective of whether a ‘search characteristics’ portal is in 
place, the intermediary will still have to seek permissions from 
individual patients. This may involve a quota system where a 
target number of patients are selected (random selection with 
replacement?). If there are further sub-categories of patients 
there is a further level of search. This might apply, for example, 
if a claims assessment study is being proposed where patients 
are matched to the inclusion/exclusion criteria of a pivotal 
RCT. 
 
Enrollment and Uptake 
It is unlikely that patients will enroll in a blockchain product 
independently of support from their provider or health 
system. Patients would need to be aware of the blockchain, 
the benefits it offers as a personal healthcare record and the 
potential monetization incentives through allowing data 
access to third parties. The obvious ‘recruiting agent’ is the 
provider. 
 
If the provider is the recruiting agent then the question arises: 
what incentives, if any, are needed to encourage recruitment. 
Providers would presumably have to spend time detailing the 
blockchain role as a secure healthcare record, the process by 
which data are transferred to the blockchain and how patients 
could monetize their data. Training programs may have to be 
offered providers so they are familiar, for example, with the 
mechanisms of cryptocurrency exchanges and tokenization.  
 
The ability of an individual patient to monetize his/her health 
record will depend upon the ability of the blockchain to attract 
recruits. While there is no evidence to date  to suggest what a 
minimum blockchain membership is required to ensure 
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commercial viability, an ‘all purpose’ blockchain based on 
primary care would probably need in excess of 100,000 
members to enable third parties to recruit target patient 
populations. This is dictated by the prevalence of specific 
disease states in the general population. More focused 
blockchains (or individual super nodes) are certainly possible 
(e.g., for cardiovascular patients) but the issue is still one of 
recruitment of a minimum number of patients through 
specialty provider practices. 
 
Property Rights 
If blockchains in healthcare are to achieve their promised 
potential, a fundamental requirement is that the patient has 
sole and exclusive rights to the healthcare data. Presently, 
there are few jurisdictions where patients are assured of the 
ownership of their health records. In the US, New Hampshire 
is the only state where these rights are legislated in favor of 
the patient. In other states legislation vests these rights in the 
provider with the majority having no legislative right assigned 
to either patient or provider. Patients have a ‘right’ to ‘copies’ 
of their health record. Whether this extends beyond the 
ability, for a fee, to obtain paper/fax copies of their record to 
electronic data transfer to a blockchain is an open question. 
 
A recent commentary on the privacy and health data points to 
the unsatisfactory nature of data privacy and the limitation of 
safeguards established under the Health Insurance Portability 
and Accountability Act (HIPAA) 1996 5. The authors point to 
gaps and inconsistencies in health information privacy 
safeguards. Although HIPAA is intended to support data 
privacy in clinical settings, health insurance and research, 
internet health data are generally not covered. Companies can 
solicit sensitive health data on line, often with only superficial 
regard to the issues of privacy and access. These data, which 
all too often are not de-identified, can be sold to third parties 
for targeting individuals for direct solicitation and messaging. 
The key issue is that HIPAA, which compares unfavorably with 
European standards under the 2018 European Union General 
Data Protection Regulation, ‘creates artificial distinctions 
between data generated in clinical or health insurance settings 
and online settings’. 
 
A blockchain can protect health data, but moving data to a 
blockchain says nothing about the privacy of those data 
elements that are still held in the various electronic medical 
records. These data are still open to hacking with continuing 
concerns over the adequacy of firewalls in place to protect that 
information, and the extent to which breaches of patient 
confidentiality are monitored. Particularly concerning, are the 
potentially higher risks associated with claims for 
interoperability where a health system aims to link disparate 
providers and sites. Where there are claims for 
interoperability, are the transactions monitored, validated and 
encrypted not only to protect privacy but also the content of 
the transaction against subsequent modification or erasure? 
 
Although outside of the scope of this commentary, a strong 
case can be made for revisiting HIPAA and expanding its scope 
to embrace both data generated within clinical, insurance and 
research settings and data generated through the internet. 
This would include not only requirements for transaction 
accounting with standards for consent, nomination of 
recipients and data collection technologies, but additional 
standards for ‘offshore’ data solicitation and other attempts to 
circumvent national data protection standards. Even with 
legislative change designed to protect data, there is no 
presumption that the patient ‘owns’ his/her data with 
attendant rights for determining access and transaction 
accounting. This should be a priority in legislation. The 
legislation should also ensure that there are transparent ‘opt-
in’ provisions for patients not willing to move their records to 
a blockchain. 
 
The issue of property rights and pushback by patients for the 
unsolicited use of their health records is shown in the current 
debate in Australia over the role of the Australian Digital 
Health Agency (ADHA). Following on from an earlier failed 
attempt to equip every Australian resident with an electronic 
health record, the ADHA is committed to establishing a lifetime 
health record (My Health Record) where property rights are 
retained by the government. Because of what was seen as a 
slow uptake (with, currently, only 25% of the target population 
enrolled) legislation was amended in December 2017 to switch 
participation from opting-in to the system to opting-out. 
Needless to say this is seen as a less than popular move given 
the ability of third parties to access these data over digital 
networks for research and other purposes without the 
permission of the patient. Currently, Australians have only 
until mid-October to opt out (presumably the unborn will not 
have this option). Also, it is noted that the current enrollment 
is an overstatement as it includes the opting-in by physicians 
who have supplied patient records for large scale trials.  
 
Management of the ADHA was entrusted to a director who led 
the similar failed UK initiative (in England) ‘Care Data’. The 
collapse of this initiative was seen as reflecting a failure to 
receive ‘social approval’ 6. An assessment of the ‘Care Data’ 
failure emphasizes that ‘legal authority’ does not necessarily 
command social legitimacy. In other words legislative passage 
‘does not equate to a societal seal of approval or to securing 
the trust and confidence of patients, citizens, healthcare 
professional and researchers”. 
 
There are lessons here for blockchains: to succeed, even if 
legislation empowers patients through an unambiguous 
allocation of property rights, blockchains as private sector 
initiatives in health care, must gain public acceptance. They 
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have to be seen as superior, not only to the numerous provider 
practice portals already in place which allow patients to view 
their health records, but in terms of a seamless integration of 
data, ease of access and recognized incentive structures. More 
to the point, adoption of blockchains by health systems have 
to be seen as a platform to support initiatives to improve 
outcomes of care and reduce direct medical cost. Although 
early days in the case for blockchains, the absence of pilot 
studies with credible claims is a hurdle to overcome. Can a 
blockchain owner, for example, demonstrate the applicability 
of blockchain platform based distributed applications in 
healthcare outcomes and resource allocation as technical and 
commercially viable products?  
 
A final point: to date, the blockchain literature has focused on 
the platform supporting potential tokenization and 
monetization of individual health records. What is overlooked 
is the intermediation role of the provider. If applications are to 
drive monetization for participants then the role of the 
provider, as a participant in data assembly for applications, 
needs to be factored into the incentive structure. 
 
Overview 
The technical feasibility of a blockchain platform as a secure 
data depository, as a tamper-proof record of transactions, and 
as a basis for cryptocurrency exchange has long been 
established. What has yet to be established is the application 
of blockchain technology, not only as a platform enabling 
patient property rights and access to health data, but the 
potential for the blockchain to support a managed market for 
the monetization of health data to third parties for research 
and other activities. There are two prerequisites for a 
successful implementation of blockchain technology into 
heath care: (i) the unambiguous assignment of property rights 
of health data to the patient allied with an unimpeded access 
for transferring data to the blockchain; and (ii) an effective 
organizational structure and skill set that the blockchain 
vendor can demonstrate in supporting the managed market. 
Capturing data is one thing; the ability to respond to third party 
requests for data access to address specific research questions 
is another. 
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